Safety and Efficacy Study of Bosentan in Progressive Pulmonary Sarcoidosis (BOPSAC)

This study has been terminated.
(Not enough patients with the specified criteria could not)
Sponsor:
Information provided by:
Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT00926627
First received: June 22, 2009
Last updated: August 10, 2010
Last verified: June 2009

June 22, 2009
August 10, 2010
April 2009
March 2010   (final data collection date for primary outcome measure)
Treatment efficacy is assessed by a composite clinical score, including six parameters: Pulmonary function test (FVC and DLCO), Blood gas analysis (AaDO2), HRCT (Oberstein score), 6 minute walk test (6-MWD), Dyspnoea (ATS dyspnea scale) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00926627 on ClinicalTrials.gov Archive Site
  • Assess safety and tolerability of bosentan in progressive pulmonary sarcoidosis [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  • To evaluate the efficacy of bosentan treatment in the subgroups of patents with and without sarcoidosis-associated pulmonary hypertension. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Safety and Efficacy Study of Bosentan in Progressive Pulmonary Sarcoidosis
A Prospective Randomized, Double Blind, Placebo-controlled, Safety and Efficacy Study of Bosentan as add-on Therapy in Progressive Pulmonary Sarcoidosis

Progressive pulmonary sarcoidosis occurs in up to twenty percent of patients who require persistent treatment, but available treatment options have shown considerable long-term toxicity and uncertain or unproven efficacy. In these patients, pulmonary fibrosis and pulmonary hypertension are common complications which have major prognostic impact. Endothelin-1 (ET-1) has been demonstrated to play a key role in pulmonary fibrosis and pulmonary hypertension, and a potential role in pulmonary sarcoidosis. ET-1 is a potent vasoconstrictor and can promote fibrosis, cell proliferation, and remodeling, and is pro-inflammatory. Preliminary data have shown the therapeutic potential of the endothelin receptor antagonist (ERA) bosentan in sarcoidosis associated pulmonary hypertension.

In this light, the therapeutic potential of bosentan as an add-on treatment in progressive pulmonary sarcoidosis needs to be evaluated.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Sarcoidosis
  • Pulmonary Hypertension
  • Drug: bosentan
    62.5 mg tablets b.i.d. administered orally for 4 weeks followed by the maintenance dose of 125 mg b.i.d. (62.5 mg b.i.d. if body weight < 40 kg/90 lb)
  • Drug: placebo
    identical preparation as the study drug, but without the active substance, administered b.i.d.
  • Placebo Comparator: Placebo
    placebo b.i.d.
    Intervention: Drug: placebo
  • Experimental: Bosentan
    62.5 mg/125 mg bosentan b.i.d.
    Intervention: Drug: bosentan
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
32
March 2010
March 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Signed informed consent prior to any study-mandated procedure.
  • Male and female patients aged > 18 and < 70 years.
  • Histologically proven sarcoidosis diagnosed at least one year before screening.
  • Diagnosis of sarcoidosis and with evidence of pulmonary parenchymal disease on chest X-ray or CT (radiological stage II, III) with or without pulmonary hypertension. Subjects with concurrent extrapulmonary sarcoidosis are encouraged to be enrolled.
  • Progressive disease, defined as follows:

    • Deterioration in the 3-12 month period prior to screening in at least two of the following criteria:

      • increase in clinical symptoms (cough, shortness of breath, chest pain, fatigue or hemoptysis).
      • lung function: decrease of 10% in TLC, FVC or DLCO.
      • worsening of radiographic opacities.
    • Have been receiving pre-study treatment with prednisolone (or equivalent dose of corticosteroid) as a single agent (≥ 10 mg/day) or other immunosuppressants (methotrexate, azathioprine, cyclophosphamide, TNF inhibitors, etc.) within the 3-month period immediately prior to screening. Patients must be on a stable dose of these medications for > 4 weeks before starting the study medication.
  • AST and ALT values within three times upper limit of normal.
  • Ability to communicate well with the investigator, in the local language, and to understand and comply with the requirements of the study.
  • Negative pregnancy test in female patients.
  • Adequate contraception in female patients of childbearing age.

Exclusion Criteria:

  • Known hypersensitivity to any excipients of the drug formulation or to bosentan.
  • Treatment with another investigational drug within 3 months prior to screening.
  • Pulmonary sarcoidosis:

    • without disease progression as defined above
    • with radiological stage I
    • with radiological stage IV (pulmonary fibrosis with evidence of honey-combing, hilar retraction, bullae and cysts)
  • Other cause of pulmonary disease:

    • Active tuberculosis (or positive Quantiferon test), fungi infection, lymphoma.
    • Chronic obstructive pulmonary disease, asthma, interstitial lung disease other than sarcoid-related
  • Anamnesis of beryllium or asbestos exposition
  • Previous smoking (> 10 PY), or active smoker
  • Previous administration of bosentan
  • Positive results from the hepatitis serology, except for vaccinated subjects, at screening.
  • Positive results from the HIV serology at screening.
  • Malignancy requiring chemotherapy or radiation
  • Uncontrolled other disease like

    • Chronic heart failure (NYHA III, IV)
    • Diabetes mellitus (blood glucose 2x per day > 250 mg/dl , HbA1c > 10 %)
    • Arterial hypertension (SBP > 180 mmHg)
  • Concomitant treatment with cyclosporine A
  • Concomitant treatment with tacrolimus or sirolimus
  • Concomitant treatment with glibenclamide
  • Are pregnant, nursing, or planning pregnancy during the trial or within six month period thereafter.
  • Have a known substance dependency (drug or alcohol within 3 years of screening).
  • Presumed non-compliance.
  • Legal incapacity or limited legal capacity at screening.
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Austria
 
NCT00926627
EudraCT - 2007-005117-18
No
Michael Wolzt, Department of Clinical Pharmacology
Medical University of Vienna
Not Provided
Study Director: Daniel Doberer, MD, MSc Medical University of Vienna
Medical University of Vienna
June 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP